0000950170-23-058840.txt : 20231103 0000950170-23-058840.hdr.sgml : 20231103 20231103161522 ACCESSION NUMBER: 0000950170-23-058840 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231102 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231103 DATE AS OF CHANGE: 20231103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aptevo Therapeutics Inc. CENTRAL INDEX KEY: 0001671584 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811567056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37746 FILM NUMBER: 231376510 BUSINESS ADDRESS: STREET 1: 2401 4TH AVE. STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 206-838-0500 MAIL ADDRESS: STREET 1: 2401 4TH AVE. STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 8-K 1 apvo-20231102.htm 8-K 8-K
false000167158400016715842023-11-022023-11-02

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 02, 2023

 

 

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37746

81-1567056

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2401 4th Avenue

Suite 1050

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

APVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 1.01 Entry into a Material Definitive Agreement.

On November 2, 2023, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 3 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent, as amended (the “Rights Agreement”). The Rights Agreement pertains to those certain contingent rights to purchase one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001, of the Company.

The Amendment extends the definition of “Final Expiration Date” (as defined in the Rights Agreement) and certain related language in the Rights Agreement to November 4, 2024. The Amendment also changes the definition of “Purchase Price” (as defined in the Rights Agreement) and certain related language in the Rights Agreement to $2.02 per one one-thousandth of a Preferred Share.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is attached as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 3.03 Material Modification to Rights of Security Holders.

 

The information set forth under “Item 1.01 Entry into a Material Definitive Agreement” of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Number

Description

4.1

Amendment No. 3 to Rights Agreement, dated as of November 2, 2023, between the Company and Broadridge Corporate Issuer Solution, Inc., as Rights Agent

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

APTEVO THERAPEUTICS INC.

 

 

 

 

Date:

November 3, 2023

By:

/s/ Marvin L. White

 

 

 

Marvin L. White
President and Chief Executive Officer

 

 EX-4.1 2 apvo-ex4_1.htm EX-4.1 EX-4.1

 

Exhibit 4.1

 

APTEVO THERAPEUTICS INC.

 

AMENDMENT NO. 3

TO RIGHTS AGREEMENT

This Amendment No. 3 (this “Amendment”), dated as of November 2, 2023, to the Rights Agreement, dated November 8, 2020, as amended (the “Rights Agreement”), between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, Inc., as rights agent (the “Rights Agent”).

 

WHEREAS, the Company may from time to time supplement or amend the Rights Agreement in accordance with the provisions of Section 27 thereof; and

 

WHEREAS, the Company desires to amend certain provisions of the Rights Agreement as set forth herein.

 

NOW THEREFORE, in consideration of the foregoing and the mutual agreements set forth in the Rights Agreement and this Amendment, the parties hereto hereby agree as follows:

 

1. Section 7. Section 7(a) of the Rights Agreement is hereby amended by deleting the reference to “November 4, 2023” therein and inserting “November 4, 2024” in place thereof.

2. Exhibit B. Exhibit B to the Rights Agreement is hereby amended by deleting all references therein to “November 4, 2023” and inserting “November 4, 2024” in place thereof.

3. Exhibit C. Exhibit C to the Rights Agreement is hereby amended by deleting the reference therein to “November 4, 2023” in Section 4 and inserting “November 4, 2024” in place thereof.

 

4. Definition of “Purchase Price.” The definition of “Purchase Price” in the Rights Agreement (including exhibits) is hereby amended by deleting the prior definition of $400.00 per one one-thousandth of a Preferred Share and replacing such reference with $2.02 per one one-thousandth of a Preferred Share.

4. Full Force and Effect. Except as expressly amended hereby, the Rights Agreement shall continue in full force and effect in accordance with the provisions thereof.

5. Governing Law. This Amendment shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance with the laws of such jurisdiction applicable to contracts made and to be performed entirely within such jurisdiction; provided, however, that all provisions regarding the rights, duties, and obligations of the Rights Agent shall be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed entirely within such State.

6. Counterparts; Facsimiles and PDFs; Effectiveness. This Amendment may be executed in any number of counterparts and each of such counterparts will for all purposes be deemed to be an original, and all such counterparts will together constitute one and the same instrument, it being understood that all parties need not sign the same counterpart. A signature to this Amendment executed or transmitted electronically (including by facsimile and a portable document format signature) will have the same authority, effect and enforceability as an original signature. No party hereto may raise the use of such electronic execution or transmission to deliver a signature, or the fact that any signature or agreement or instrument was transmitted or communicated

 

through such electronic transmission, as a defense to the formation of a contract, and each party forever waives any such defense, except to the extent such defense relates to lack of authenticity. This Amendment shall be effective as of the date hereof.

7. Descriptive Headings. Descriptive headings of the several sections of this Amendment are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions of this Amendment.

8. Rights Agreement as Amended. From and after the date hereof, any reference to the Rights Agreement shall mean the Rights Agreement as amended hereby.

9. Severability. If any term, provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in full force and effect and shall in no way be affected, impaired or invalidated.

[Remainder of page intentionally left blank]

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the day and year first above written.

APTEVO THERAPEUTICS INC.

By:

/s/ Marvin White

Name:

Marvin L. White

Title:

President and Chief Executive Officer

BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., AS RIGHTS AGENT

By:

/s/ John P. Dunn

Name:

John P. Dunn

Title:

Senior Vice President

[SIGNATURE PAGE TO AMENDMENT NO. 3 TO RIGHTS AGREEMENT]

 EX-101.PRE 3 apvo-20231102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 apvo-20231102.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 apvo-20231102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 02, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 02, 2023
Entity Registrant Name APTEVO THERAPEUTICS INC.
Entity Central Index Key 0001671584
Entity Emerging Growth Company false
Securities Act File Number 001-37746
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-1567056
Entity Address, Address Line One 2401 4th Avenue
Entity Address, Address Line Two Suite 1050
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98121
City Area Code (206)
Local Phone Number 838-0500
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol APVO
Security Exchange Name NASDAQ
XML 7 apvo-20231102_htm.xml IDEA: XBRL DOCUMENT 0001671584 2023-11-02 2023-11-02 false 0001671584 8-K 2023-11-02 APTEVO THERAPEUTICS INC. DE 001-37746 81-1567056 2401 4th Avenue Suite 1050 Seattle WA 98121 (206) 838-0500 Not Applicable false false false false Common Stock, $0.001 par value APVO NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports apvo-20231102.htm apvo-20231102.xsd apvo-20231102_lab.xml apvo-20231102_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "apvo-20231102.htm": { "nsprefix": "apvo", "nsuri": "http://aptevotherapeutics.com/20231102", "dts": { "inline": { "local": [ "apvo-20231102.htm" ] }, "schema": { "local": [ "apvo-20231102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "apvo-20231102_lab.xml" ] }, "presentationLink": { "local": [ "apvo-20231102_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_f9edafd3-e782-4c9f-a518-e418ed5ce662", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20231102.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f9edafd3-e782-4c9f-a518-e418ed5ce662", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20231102.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://aptevotherapeutics.com/20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-23-058840-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-058840-xbrl.zip M4$L#!!0 ( .B!8U?OJTH<[!, -V] 1 87!V;RTR,#(S,3$P,BYH M=&WM/6ESXS:RW_=78)W=E*>>(8$W*7MFR]%H$FUF;)>E'/6^I$"B:;&&(A62 MLJWWZU\#)'7X&/F0;=HC5R4CDC@;?:/1./C/Y3@FYY#E49J\W]%:;(= $J0B M2L[>[QP.NOW^SG\^'/R34O+Q4_^(',$%.0R*Z!P^1GD0I_DT [([^/*.]),X M2H#\^=/I9_(Q#:9C2 I"R:@H)IUV^^+BHB7"*,G3>%I@5WDK2,=M0FG9=C<# M+E^3C[P TM&9;E!-H\P8:G:'&1W+;NFZ[OT/8QW&%K72R2R+SD8%V0W>$5D) M>TX2B.,9^10E/ DB'I-!W>4>CC%HD<,X)J>R5DY.(8?L'$1+-OF/@U&!L$!X M)/G[G:5Q7QBM-#MK:Y[GM2]EF9VR4.?2SV(1SP?[U&\7E9Y_G\^*7U\JOS$]^K8M&E[>UJ\EA MR/66RUT73]+D")<]BX*;JXDB:Q>S";2Q($W*DO-1Y=%-8\(9:.T_OWP>!",8 M4\+(.H?(583D+)]B?E;- M[;(XA1!G_5?H@>"AP,8<5Z=FX(646YI+P=1<$!:V:2,\0Q[G<-!>&7"]!!=EUL7193SN)P(N?X79PP;) M$.]M1[-<\]I(VZL@S2"$##DVY!\.).UVUC"7=J'>C M3 Y&XB&M$:UUF0MKK4\0@*FHGY"39(44-Q_FTD:OZRV^S83C*)YUAM$8I6BW'6C> V^<;8/.079UQ MD,9IUJF!?OO\+T#J$QT_C<7R"-T' N2WH_ZP]Y$,AH?#WN# SY!?#WK=WT[[ MPWYO0 Z//I+>G]U?#H]^[I'N\92: M%^KL06)\23>H+2*EDS4"H$J+K)#KJHJQ)=%G)%&O813Z4'Z/ NJT=S0DI[V3 MX]/A\T+%QM)-AFJ$)82.>0 MH?W,XPH)L)&;&,.],?%^[&N%-^$7J<\@WG76R>-U [E%'G/-$=S078I"%F4K$P%UN6Y3CS'; MXX'!.%B;DLG%\C3?Q7LHK-R/G[FE_?G:3_GJSQ32LUBZYT\V%LQ;&1 M26AV0#W=%]1$Q9YRYOG4UP-@GLMM2],>RU9*%^ IG$6Y= ,71_AEH]QB[>1O M6];#DV'O]V,R_*5W>GC2^VW8[PY(_ZC;NJ<-<-?U-YJEU#JMM0AY"]QV>Y<< MM3"YQ*5LK)>6\)P,)A!(CZ,@44+Z14ZZ(XZB,7NW:1/JOC;"EK6^&M;:1$U> M7U7D;U#UUWQ?WX"[IH"I/=26P-E) +_?,7;>D%UQ#P'Y4+T[Y#HW>.!0 SB@ MWJUQE(V6H" 87/(-[:-UOS-1]!I1TN>L)\*7Y7'J M^9Y!]4 +N"4LYEGN9O!KR"_[U09UH-A>DY#-U:AFV0ZS[H-MWQ#)SNN0R*55 M\'3X^6(VBQ*ITL-\+ .+R'^G692+2+F>RVUBM&169/"[5\%.WNQZ==/Q.,IE M"":1F-)W$Z@ZRDFE4&3H[2UHU+M,P8F[EF3RR7G\U^ M;BY5;"&\A? 6PEL(?V<0WKKIGMYFM41HA0%WJ6;:!C4AY-35&*,0AH[IF;9M M!N%F;-9#(3+(\^J?SU$"6C/L5=UD&C&+$3D\AV1Z%Q?D^U['HSEGTPQ8Z(QBQV7Z?8G-GHWQ6SV0J YJW) M!N*CP#>%)EQJN Y04]M&0K9:3.7[Z*+;H_>#Y"=E*D25,V49Z5_[QH:,/3P[.<\MMD\0RU/8.9#@TUQZ0F MMQS*==^DFL$=)]0X9[J_40(_29&"X_^-)FH'OA'4Z[F:KFWWH]Z"*[U",AE M=Y*A (DF/":]2PBF,I,$.0[#*(#\=>QWO#F5O7$0?K-D@.R52/[ZS5VC&T/R MW[:NT-0PR$T?:-)TZQ6RK%=\HFD1K?WC#YI==I45*)[* M92*'N!Z*0CL;,"(3:2+%FYC&$UF1FNOZPF0P/E4PP;,J%&5 6A&$0.HZM M._9CE4SI.I!0;8Y:N:LS^]W3N0X:O^J![1HV!TXUU\ 5U/R ^IH=TL"T?0U MN*;_Z%7_G"+3.I%$UJ@H-\.ES&+W<1YOA?)6*#=2*#^##R(0H#D. \I"Z68V M4$8@VW"IH1NAP4)N&&Q#3L9^,D^7]@E_0/89SGA\G)7B&S(0&S]']XA3MP4Y MG$QBQ !_K0NZ.:RD8990NS^EN(@B^]D/7D-DHD@X'SAIHA%18M98!#P X123V-"_Y8?!Z@( P0[LG9 M%V2LR%WC+3(O1R_,P4/&%7RN8[)FHH&N+R'S2DZH.2J;:+^HDM\G-IN>QRS7 MT2CWW9":-B V([^FH6&;H1^8CNL\VD0YR4!R9IG^5B7PDPI =AR&D&VQ>CG+ M&38?+,%I+:_63$'U7?_=W7"\+/M]8KD6FK;G([)RYMG4] .@7/?[L<1ZW+Q?Y(51_S-A&/VYIY/EI9)AQ"?4J MC?YLC.WNOD"HV99 M@323 (I*>.H2G"H9 C4RBDJ5#@.?+/0NAYYZJ=)@8:- MWX)U'->5? M&%+/<2VJ.P BM%T?/VY*X-8>0!7;=,V]*E6P39REW!PQ#T= CG@N^-^E4"9? M>/85"O+Y<_>YPZ#6W\5R/])\,9CV$R&]QD#\&0E46 J._"OJW* 2]UV)&8ER M@F,&!.Z9W#T\R]*+8B2=SQ,91\)S(B",DC(;>;D?SJP;KI=9W"ICD%W)/9Q] M%1ZOA_MJ;[RNA-TAADYD/G,9I%5ZLG6?ZG>\LN9:X]*[O:B_U'RK4>[]JW$N MSWFC4Z.PLW<+IMTA,/VV)"8&FML\TW0K\4 2/OFJM MC"FMQ_ZS&GJW'/G+[V)]YQC5#[_!P?:0;]W(#J-KT7,C9'800U @LTM2M0$T MS4&5PIE7,7KR'N9(;0J5E[+*Q5=]Q3/9^46$74MT3G#8^"6#\RC'>N'\YG > M!#(MN2PL[YT6/!-Y&9TG;MM],G;Y?/=IF2>V'G^:XRJ&/M&]<1ML MO5>"8Y0M%-XS*+5;RD,4,AT>7_!9OE_>?OT0I6/M38M/' &[*8=?OX QT= & M(#V95?QS+K:W7M5G7KUAXY M5%>XD^'2'>[R3&&+[$HN4)X\#/8K$50^BOUW1)DP2EE#\,\O-I=998FQ6G7^ M<5$9J\@2IW)^^6*9]HB\M4Q(71"9T'RHKAHJVR,^%!=H4JBZW5IO3 3Y*4NY MR")Q)E^76:&!E$$@9)#&4Q77H$Y*MO9DX_-^59_X@H]+IKLR[JNCFP^_)8%U M;?"231<\2O)R=BDR]*!\HS0"9,.R4%;6PB+(@)'!YM)+K?ZC6&>:XW20K^/L M. M@6Q+#*6>_&A%^6W 0>+R@GY+_2-7^"(J3EJ> *C)XA,J&#+]Q20JDZ\3>?=@ M31MD=]6.NXG*WRF:K6DC@UC1?(RZQA2%WFVU),G,.8*I.(+9(F1U]#S.4U*J M+=^:PDE->B>HW3[3V/^EMY@N><2M]+Y$R)+RWYA5^3:(A2S];2%2LP^T3. L ME<)(0!YDT63YU-"".D6*+4I[!T6?NJ,5R<*'TJ8!E-B2M**<_#W%:=;7TD5( M1U@WRJ"82;M*T8B,7*QUB'EM":!K?:)TQQ(3=4RIW J67JBBX&B?*3VC=SF* M_*@@9DLK6\3OW2E285*?V).[R//#5&J(\ZLGL G4F@"'N3RR9LG79I_,>TD: MV*A!8K28L;!!OJ1B<=&"#*,M!8+2Y4KW.?D%>XJ3.VB_@8K4P="ESB9:E]56B#TEJTU8*HOR=8\B7^? MYBY%E4A5(EJN)&$E/+=,[)6@QN:8V*YX-U_]1D'DY1+,+"=PX-,BW=_<\8R5 M0UJJ[/%KFI=*[J'Q5+QZHO%V=6^[< MG1O'#0U#?A/+M3DI9[:T9Z>EYBP!)Z-,QC#PR7E*X=+\2VN-BO'M:Q.&=UX; MU9N H+J_LZ,LGSA*8"-AFUV&,VFF[99YHC$M]2?;.I7F/F M=TSUC5B"+E*DW.=$.NO+?68>*#_'1U[P\HK974FP0F[9RCB8:MNEGT@60O[\ MZ?0S$6DP51LVS4MF]^)FRQ-&F=P'*%56MJ8>+!OT?SXZ'/YVVAL\IX%['2B- M(LR3I:BQ,JCM[VF452ZAN\75[MT4#2>F\8P$?"HCV)0/,H.E':(Q^KY1HYVW90Z"\R@AGUOD#]GQ&Y):KUQ7V,)S M"\\M/.\#SY9S+[[<\'V.JXQ9)1D\R2"/A#IGE@C2'4407KL&^L;@J^U^XYWV M&P_:?BIF'_YQT!X5X_C#_P-02P,$% @ Z(%C5[:\A!X4 P M@D !$ M !A<'9O+3(P,C,Q,3 R+GAS9+U6VV[;, Q]WU=P?MJPR9<$+5:CZ= M*Q @ M[8:D _96*#:3"),E3Y)S^?M)MI4ZO01I!RPOD4D>GD.1DGW^>5-P6*'23(I! MD(1Q "@RF3.Q& 0_I^1R^G4T"CY?O#E_2P@,KT8W<(-KN,P,6^&0Z8Q+72F$ M=]/K]_#KRV0,TVR)!86AS*H"A0$"2V/*-(K6ZW68SYG0DE?&TNDPDT4$A+3) MORJDS@Y#:A#27MSKDR0AM*/,!)9")>254,<4XK;@9! M)?Y4E+,YP]SN,D>W/7L!';=MB] IBJKH[6@W,\5#J1:.*(YP8U!H-N-(7)C5 M4M='>JZ'#9R6*WF\Z 9CR]]!7,?6_98R3J)?U^.FNSZ8,_%[+[HC,>Y'SCVC M&GUXI$;B M3"3ID7X2VF0!B$=3=T!N]&\B?)]>)6+7Y->*\$UR["?/\3[9U:,8]7/SXQ;$ M+0YR/IJZEY$^.>(1-Q=IYSK!$N%\T'@+AGB;Y$[3F>A/3L^Y!'!_NPX M=V0AR,?W\CS6,./ 8^?64)\U[]F6UJ'M_O-V[/Y[G:7"E]9I(=K>^'6WGB_W M1R?JZ*)=_EOK![?X.1D=>^E'AFZDD,6V4>C?V?[_4N3?A-6U'=EQ4D6M*0!F M7Q 3&WYW5+@7ZJ7F:#\!6#VQ2>Q^]@.A\ZVP6]IDT&2#3KKSZ&&2!^DKC?EW M<5&O'VYX"VY##@ SRK.*OQQW+^M96&OT#6M/;?3@V+:&SN%N+,U5<_$74$L# M!!0 ( .B!8U<7R=C@[@4 ,LV 5 87!V;RTR,#(S,3$P,E]L86(N M>&ULS9MM;ZI(%,??]U.<==^TV2*BNTUJVMZXMKTQVZ=4;_9F-YL;A%$G%Q@S M8-5OOS/#0P4&M-H!7Y7"F?_Y'6" ^??TZLO*=> -41\3[[IA-%L-0)Y%;.Q- MKQO?AEIOV!\,&E]N3JY^T32XO1\\P1-:0L\*\!NZQ;[E$']!$9P.'\_@^Y^O M#_" O9]CTT=P2ZR%B[P -)@%P;RKZ\OELFE/L.<39Q&PA'[3(JX.FA;)]RDR M^7ZX-0,$W7:KW=$,0VMU1L9%M]7I_G'1O# ZO__6:G5;K8UA9+ZF>#H+X-0Z M SZ*Y?8\Y#AKN,>>Z5G8=& 8)SV'@6) MRUCYN.M;,^2:#\02>->-C7I68^HT"9WJ[5:KHR>C"B/X;UH-_'%=-4Z/S0^;SY%[QYQ*<-+'E>/T<;#NL3G8)S:2G9S- MP\IAXL?'"Z*8V'>>S1\*$BIY7&5X(Z980B4.*X>Y\P)^;6R;(M^/?K!9A@P) M67%L;9CM#V"V*\;D-_TS'9&EMPUR([):Q!?"'M?./WA>,&]+@JL%'09L:C[3 M%TK>,'^];$'-AE<$VV?3EIK.@+V05G^A=2%E-JXBO#L7T2G[//M*R3*8]8D[ M-[UB2'ET1:CWV$%/"W>,:"'?1DA%4.SCC] YH>)33MQB?;)@5W)=.GO*1U6& M/B'4%0CW; /1!S0UG6?ZBJ;8#Q!%]I/IEM6PT_"*B@FS4M,+2J$S817!C.R],43+1>B'.J%LMGALL\?"_%OH('O+Q = M\2]\^CR92"&W#JD:^D.XE8(.D;6@[)XSVN,17U5)\'(AE4'=K:R9Z4U1P9R6 MAJF'(PZV<,!>@X_LP4VQZT*9!' -X")J,*6+^3UY M$_\Q% .F)HQ%M>1\P7\H,-=00UFX^-\3.=2#2.D\WN F,()GK^(JVBJJ&"U) M!56\FP>?5(.8K80"EZR /V4K?%()H28P485/G#+'X9/J$*K\6L2Z*BO)N!*' ME1")@5 #)J>27&I5',8?2T*H"9&HRBK>#8T]T:-/9(Q\_EF-V1 E4#ZW=[,]#JTQR7$.8180:7BA[XF 9U)9:]HM.:RF=RWEV 7V MR6'\3!32JDKG4=9FV1->R(#048J[S7#9$Y_):M:&+H3"$"J#D*ZD( 6EJ*\A MZ]OL22[& IF T3X=GT&LJI9YT](Y[-7'WMN1EL('3][NV1:"%&-'Q" MB2MK$XG3D2+S*N^,50$I;2Z)(?.^53V0LI:3Y$1F/:MZ$$L;46+68N.J7NC- M]I0L:V)5U8.XM6DEYBTWK8X+OKTK?/M8X/,-+E+TC$%U!.#2MA]Z<.@+\ M@F88:0$R7ZK.$@I:9-+L,B>J3NC2QIDT>K$556JH3=:JWH(^TGJ3K6QG ZK.$N4-.>E2)/Y2G MU%U;>F+TG>REHRAE]R*. [^H_2>&EGI(]:+*FH*RN#G[J";DPE:A!%AN'-6# M*VT@BDGSAE$]D*5M13%LL6LDH#&ULW9I; M<^(V%,??\RE4]V5W6F,;NNF&"=FA).DPS6V G>[T94?8!]"L+'DD<_OV/3(8 M<[$A><"M\Q(;ZTCZ_:5S=#F3ZR^+D),9*,VD:%E>S;4("%\&3(Q;UM>^W>YW MNEWKR\W%]4^V36[ONT_D">:D[<=L!K=,^USJJ0+RH?_XD7S[H_= 'ICX,:0: MR*WTIR&(F-AD$L=1TW'F\WDM&#&A)9_&V*&N^3)TB&VOF^\HH.8[N:4QD&;= MK3=LS[/=QL"[;+J-YJ?+VN?Z9>,7UVVZ[E8U&2T5&T]B\L'_2$PM[%L(X'Q) M[IF@PF>4DW[:Z:^D*_P::7-.>J:6)CW0H&80U%9MQ5#QFE1CI^ZZ#6=3J]#"_+)3,]M\LKVZW?!J"QU8!&=#Z*3O5W22 MFB\.[.>-Q-J[NKIRDM*-J69YAMBLYWQ[?.@G.FVCF)1G49$#QQ_>.Q#6@/=2QHGZPC6M31P:0-SC;Q6>'29WK!123Z%^!62QSJ/+M2L,; M8(M'J)+BL\.LHJ\=!!AE>OW * ,OAZS8]C_#K+\!LUXRIG'Z9S603SIR#"BHA@RW[HDU'O&X6D:#D$5\FV9E 2%AV*I M(JF2HTCB8ATYQ9E<'HV>X[5*0]\V8EP0WHHAM@?+,16]V%3KAQD?W9<&KY]$H%_)DE;*AWX1;*F@?_*E"G_/JPX&Y7.7@ M'9B4!G6W\"=4C*$@IG/-S@\G.?-9C-O@(R[AW9H=':P@:(F ]5?AD.9 MQ[1;?G:Z1DF'=O3WN3>;=H(A7&:LOR7-=S31XPPGNC\0J488 M&1GL?0?X/TG:O:EO%'F-RBHJN.YGDU6OO+15JB!3Y%96T9%\0R;OZMW)J^_( M\]Z%O.W\1K:.O!/7W,N,9/JJNY@<3ZAD"JN[MQ5D8;+(^ZWBT@HR.)G 3Q47 MN)WWR51=5ES5B<11)O3WR@M]79HI6VRJ[K#[N:AL+JM[H#Z1R,HD?JZLQ,/D M5^:2U=TD3F?/,I75/6,?2[=E^JKKFX=9NHVJ>G7/9OEIOHVR1G6C+B]'F/EA M=;?TO11CYH35O0(5I"FSV7K=2?/:.5"&E_P?-Q?K O/'_/O9S;]02P,$% M @ Z(%C5RJJ^T87"P FHT X !A<'9O+65X-%\Q+FAT;>U<;6_;.!+^ MOK^"UVX7+> XCI.^K)TMX$VX?%?: EVN)6$@62BN/]]3=#2O)+ MG#8-DIJ;LD#@VJ+(X<.99UY(Z3C22?SV)W(<,1K")SG67,?L;?<_>T?U@^-] M^PVN[Q<-CBXK_S5H'C4RW;7][6F3EM2E->+QHC7G"%.FS M.1F*A*9EPXG06B30UO1*8SY+6S&;:ACT&&\O!YU'7+,]E=& M3+)]N:29JMC M-V'L+PX'8\UYJ*/6E.N] %J"^##(+T\/7C7:Q_MX[]OC_6Q]JH60*%#KJ/[R M\/!9^\%G+_DLNC9]] MDQ'I]4_JCL'V0^G(KE3A0[=_"G]CTA_4R:$'!4$9#\BP=_YN/"*=\V&WB_#L M#)AM7O8;84F!=&B\*MS!'8$ACPN&N^H'V?@WCK@BG82E(?QITA=@2>2YQE]_ M>7K5;!P$%=LXH-V5H/<@T_UA:H$*VR]J)*2:A80J(J: Y25+)DR29HTT&\W# M&M&"Z(B1(8X/J,\D8SB9\K;JAC?FAD8-.Z(X9;CX'.]T<$DV)^/JRDR8GC.6 MDDZFV:4 O6!/Q%)1M.%JWC3 M-"2_2T%#R<,9(R<%HHSTE,I!QT_6-[]4^0'G4[HYIQ-P51D(0NR%2*A&CHU?@B_%20TL6&N8F0UMML=5*$ MIX0&0(PA30-&YEQ'IETFQ257:,CH\T8L,*39?(T7)1/3-C*!4ZOD%=(1A0R9 MXA*Z U6T>AU>S)ZO= M&96:@_BHE*#9^#%9V*Y1:Z A98Y1I5^']E\O8RG;22# MX0]8/$\5."GLYX;;CJK;T)'%%,>PD9!;_FEW2N]A6+7]IG.V7^Z\_>Z8[5=R MW51'^XKATSA>&KZJK/HV#. MWUO^O5O^H;.6?^*HY9_1?-<2MI/&W8)),51Y$*R1EZJL_-^N-YK?T67=JH;R_ M]S#\$\CP+(?,X$S(P-ID=SH%E^^4)6$(%+#,E+W9%0RF5+PD*,M7M>TDIR+, M>[ KGN8,N7"*TYU6TV5FNK?8WG$RC/%6[895OW3.JL\A+IC42YKCS8L^>B D8B]GVN;Z)N(;YG0%90Q]7_;]"?KXG M4$R_GFD]TUYGVE?.,>V)R/$$-&Y\JC8YHX'B<#_DN88AD"B-^U!: MB'"%48N]ZI2!,*F U0"U7_:S,GR==,Q%JG-I#P^MHU;!!9,UCXLD7.-72)P# M+44*E!@#QZVDW$"WTU)5[*R)>38,F3,4@1$?L4NH7H[\PJ(0T4NV%)/FD!9+ MKB$$+H)9LRJIB7'IA,=PR1RE7>*\[+%.^L+@L"AW[%$!).7*CI K5JWM/@ _;E= -"J):2H)%70#E^6:TCF(/LJ MI@)7/TER!!6^.V5.FV0=R5*DC,[8WD0R^GF/3D&K6C2>TX7Z[L_^;7WZS5=# M'UXU="1%/HNNF=*J]=@C[UA<8ZEB9;G?LD!1:EN&Q;4E^UH#QH,]:'=S"N:G MK('A8$5W0 \VBRZZ!9Q,)+C2! ++&&S*G$F+:?#9# CT@D%: #12O_;$1!5' MLM+%%VX84Y M,LBH*2X(66:,0<50P#N%.)LG65<%\8S@&>$Z([QQCA&VG;WNV-*S8\1PAD\W MF%0" \Q-#UPSAKEV].\+%7.T[QN/GJ]7WKTA>T.^;LB_.F?((^,;;3[LF.7V MK-<$JTUJ2Z=9 ]<*GIG:C%@R\+(\6)[D7_/J9M\^ME5<+%Q(;6LU2<9,E+]6 MN8;>A*FB5*6#HA3#TTM0J;!&+@4WB7:>5G6$F-6*DT0)Y:867SAYE%JMB*V6 M9)1+6Q\HYH'E ==> MC?'@6F:;XF MKD&2X$:]^W.XNI18H #@\!HLE"E7(;&024S3S_]S#,4?J&#Q MM:DV[G.JOEZUR^7_*U>:3Q?.^/)>GWSJC?O=T<@^P3@XV_Z,%Y:C YHKMOE( M6.%6PAS(I"J1K]:';+*Y8%22*9<*:'X"KH/,)99Z=_A(HVLKL1E#_ M?=%Z6,TN(K@2B/KKEQG,6L0\).5T;X6^TR7)NV:Z^VJ??*#RDJ?D$X[J;6&7 MMM"G"7M@:_AQP2W4_'W=:_KN%V.,+X;WJOY Z%Y(AN\V*EY%=!)Q-B5=>RSQ MDI'!=,H#)K]D /")91$'2KQ.A(4>!@^#+S+Z(N,NTJ/AH',Z[)V>=\G)8'@Q M&';&7=(;C3YVAV0T>/]QW!OT1S53=ZR1SFCYBO?UU[O[$,>-NH('UA=L'B/\ M'EBOU_]P^'TA%R'^+*"47=7*:IZFW!5^(?*2J[M7<%35WI@KY*/5\Q%)\ M'=H?/,#7KA452?>JCCLZB^Q>P" ^$!\(#X8'P0'@@/! > M" ^$!\(#X8'P0'@@/! >B$<.Q,9[=7Z](PI_CGKG_<[XX[!++CKG73(>D,Z' M;O\4_L:D/ZB30_RI.K(W[';QRN8+16[WXHGC_8D(%V]_.MZ/=!*__3]02P$" M% ,4 " #H@6-7[ZM*'.P3 #=O0 $0 @ $ 87!V M;RTR,#(S,3$P,BYH=&U02P$"% ,4 " #H@6-7MKR$'A0# "V"0 $0 M @ $;% 87!V;RTR,#(S,3$P,BYX%P 87!V;RTR,#(S,3$P M,E]L86(N>&UL4$L! A0#% @ Z(%C5TR"X!&[! /2@ !4 M ( !?QT &%P=F\M,C R,S$Q,#)?<')E+GAM;%!+ 0(4 Q0 ( .B! M8U